SLIDE 1
10 tips on how to access EC funding from a patient group perspective
Oliver Timmis & Dr Nicolas Sireau, AKU Society Dr Tony Hall, Cudos
- liver@akusociety.org
nick@akusociety.org tony@findacure.org.uk
patient group perspective Oliver Timmis & Dr Nicolas Sireau, AKU - - PowerPoint PPT Presentation
patient group perspective Oliver Timmis & Dr Nicolas Sireau, AKU - - PowerPoint PPT Presentation
10 tips on how to access EC funding from a patient group perspective Oliver Timmis & Dr Nicolas Sireau, AKU Society Dr Tony Hall, Cudos oliver@akusociety.org nick@akusociety.org tony@findacure.org.uk 1) Preparation Research in Liverpool
SLIDE 2
SLIDE 3
2005: Post-mortem of a patient 2009: AKU cell model 2010: Natural history study 2011: AKU mouse model 2012: National AKU Centre
Led by Prof L Ranganath, Prof Jim Gallagher and Prof Jonathan Jarvis.
Research in Liverpool
SLIDE 4
2) Find the right partners
SLIDE 5
DevelopAKUre Consortium
Vital to identify the right partners: ideally you should already have a working relationship
SLIDE 6
3) Find the opportunity
SLIDE 7
Announced in 2011, for projects to start in 2012
FP7 Health 2012 Innovation 1
SLIDE 8
4) Understand the application
SLIDE 9
Application Process
Two stage process: Started in May 2011 Approval for funding Feb 2012 Stage 2: 125 pages Rigid structure:
- 1. Scientific and Technical Quality
- 2. Implementation and Partners
- 3. Impact
- 4. Ethics
- 5. Consideration of Gender aspects
- 6. Bibliography
SLIDE 10
5) Read the guidance (again)
SLIDE 11
Application Process
SLIDE 12
Challenges
Registration
Partner Identification Code (PIC)
Content
Motivating partners Strict templates
Project Budget
117 page document Eligible costs €375,000 rule 30% to SMEs 10% Management Categories (RTD, Management, Other) Conversion rates
SLIDE 13
6) Get external support
SLIDE 14
National Contact Point: Alex Harris University of Liverpool research office: Dr Nick Rhodes Vincent Grek, Only For Children Pharmaceuticals Liverpool Ethics Committee
External Support
SLIDE 15
7) Regulatory
SLIDE 16
Orphan designation
– Ensure adequate data – Get an expert to write / review – Apply in time!
Scientific advice / protocol assistance
– Ensure underway before H2020 – Apply in time!
SLIDE 17
8) Clinical
SLIDE 18
Proper planning of CDP essential Think through all clinical issues
– Natural history – Efficacy measures – Surrogate endpoints – Number & size of studies – Logistical issues – Specialist centres – Ethical issues
SLIDE 19
9) Implementation
SLIDE 20
Project Implementation
Two representatives from each partner join the project board: DAILY Workpackage leader WEEKLY TC on Thursdays Minutes stored online 6 MONTHS Project Board meeting 18 MONTHS EC reports
SLIDE 21
10) It’s a marathon!
SLIDE 22
“These trials have given us great hope. This treatment could completely change our lives. We’re that one step closer to a cure.”
- AKU patient
SLIDE 23
Contact us:
- liver@akusociety.org